News

An epidemic of chronic diseases continues to grow in the United States; half the population — an estimated 129 million Americans — have lifelong health conditions that need continuous medical attention and limit certain daily activities.

Whether your favorite summer activity is taking a long hike on a trail, catching waves at the beach or having fun at a backyard barbecue, the warmer temperatures generally mean more time spent outdoors in the sun. But because more exposure to sunlight means more exposure to the sun’s ultraviolet A and B rays, you need to take steps to protect yourself from cancer-causing ultraviolet radiation.

In a surgical suite at Barnes-Jewish Hospital, a robotic arm snakes an ultra-thin, ultra-flexible tube through a patient’s airway. Once the tube reaches the lungs, the surgeon operating the device remotely uses a tiny camera to search the area for an abnormal growth, or nodule, that might be cancerous. Once located, a needle pierces the nodule for biopsy.

For neurologists working with patients with Alzheimer’s disease, the road to actual treatment options has been long and paved with setbacks.

But that is changing for some patients. The Food and Drug Administration recently granted full approval to Leqembi® (lecanemab), the first disease-modifying treatment fully approved for patients in the early stages of Alzheimer’s disease. The development of this new drug offers hope to patients and may have lasting impacts on how physicians approach treatment.